Saturday, February 8, 2025

CATEGORY

ABPI

Government Must Empower NICE to Unlock Access to Life-Saving Medicines for Severe Conditions

Key TakeawaysNICE’s decision to maintain current valuation methods for medicines leaves patients with severe health conditions at risk of missing critical treatments. The...

ABPI Welcomes UN General Assembly’s Renewed Commitment to Combat Antimicrobial Resistance

Key TakeawaysGlobal collaboration on antimicrobial resistance (AMR) was emphasized at the United Nations General Assembly during its 79th session. The UK's leadership in...

ABPI Preparing for the Windsor Framework: Ensuring Smooth UK Medicines Supply Beyond 2025

Key TakeawaysThe Windsor Framework, fully effective from January 2025, introduces a two-category system for UK medicines, increasing regulatory complexity between the UK and...

NHS-Industry Partnerships Improve Patient Outcomes and Prescribing Practices, Report Shows

Key TakeawaysEarly research suggests that NHS-industry partnerships significantly improve patient care, with hospitals up to 2.5 times more likely to follow NICE guidelines. ...

Clinical Trials in the UK Get a Boost with Innovative Pharma-Government Partnership

Key Takeaways:The UK government, NHS England, and the Association of the British Pharmaceutical Industry (ABPI) have partnered to launch the Voluntary Scheme for...

Agreement Reached for UK’s Voluntary Scheme for Branded Medicines Pricing and Access

After months of negotiations, a significant milestone has been achieved in the development of a successor to the Voluntary Scheme for Branded Medicines Pricing...

Latest news